Masuo Ohno Aims to Explore a Cognitive Paradigm that Allows More Sensitivity to Detect Beneficial Effects of BACE1 Inhibitors in Presymptomatic AD.
New York – Head of the Ohno Lab at the CDR, Dr. Masuo Ohno, publishes a brief report in the open access journal Neuropsychopharmacol Reports (the official publication of the Japanese Society of Neuropsychopharmacology). The report, titled “Accelerated long-term forgetting is a BACE1 inhibitor-reversible incipient cognitive phenotype in Alzheimer’s disease model mice,” provides experimental evidence that accelerated long-term forgetting represents more sensitive memory testing that can help evaluate BACE1 inhibitor therapy in presymptomatic AD populations.